SCHEMBL3321487

SCHEMBL3321487

O=C(Cl)C=Cc1ccccc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.70
JUN P05412 1/20 0.70
NFE2L2 Q16236 1/20 0.70
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
CA4 P22748 1/20 0.68
MAPT P10636 3/20 0.66
LMNA P02545 1/20 0.66
BCHE P06276 1/20 0.61
GUSB P08236 1/20 0.61
MAPK1 P28482 2/20 0.59
CHRNA7 P36544 3/20 0.56
AR P10275 5/20 0.54
CDK4 P11802 1/20 0.53
CCND1 P24385 1/20 0.53
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3321477 1.00 NFKB1 (0.70) NFKB1JUNNFE2L2CA1CA2
SCHEMBL6907589 0.87 NFKB1 (0.50) NFKB1JUNNFE2L2CA1CA2
SCHEMBL1160537 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
SCHEMBL1160535 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
SCHEMBL3329177 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
SCHEMBL29539991 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
O-Coumaric Acid SCHEMBL29367602 0.81 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
O-Coumaric Acid SCHEMBL29368085 0.81 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
O-Coumaric Acid SCHEMBL64885 0.81 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
O-Coumaric Acid SCHEMBL892006 0.81 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 US disclosed
EP-1787985-A1 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom Unibioscreen S.A. (BE) 2007-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 NFKB1 1071/4885JUN 3531/4885NFE2L2 475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.